drugset / Trial / NCT06354140
PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY
Phase 2
Recruiting
45 enrolled
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
NaSingle-groupOpen-labelTreatment
Summary
To explore the safety and efficacy of Tegafur combined with tislelizumab in patients with esophageal squamous cell carcinoma with residual primary lesion and node-negative after radical resection following neoadjuvant immunotherapy combined with chemotherapy
Timeline
- Start
- 2024-05-07
- Primary completion
- 2027-05-30
- Completion
- 2028-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tegafur | Unknown | 80 mg | Oral |
| Subject | Tegafur | Unknown | 100 mg | Oral |
| Subject | Tegafur | Unknown | 120 mg | Oral |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |